OACC
Oaktree Acquisition Corp. III Life SciencesPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Aug 31 Short interest falls 85.4% to 1.3K
- X Sep 15 Short interest falls 83.6% to 208
- R Oct 15 Oaktree Acquisition Corp. III Life Sciences filed a DEFA14A disclosi…
- R Oct 15 Oaktree Acquisition Corp. III Life Sciences disclosed that 13,326,97…
- R Oct 26 Oaktree Acquisition Corp. III Life Sciences (OACC) held an extraordi…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 1 trimmed or exited.
- Short sellersSTEADY
Short interest +1.1% to 193 shares. 1.0 days to cover.
- TrendDOWNTREND
1% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Verition Fund Management LLC | ADD | $5.0M |
| Schonfeld Strategic Advisors LLC | ADD | $1.5M |
| UBS Group AG | NEAR_EXIT | $16.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 23, 2026 | Oaktree Acquisition Holdings III LS, LLC 10%+ Owner | CONVERT | 4,798,758 sh |
| Oct 23, 2026 | Oaktree Acquisition Holdings III LS, LLC 10%+ Owner | CONVERT | 4,798,758 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
6 filings · 0 bullish · 5 bearish · 1 neutral- BEARISH 8-KOct 26, 2026
Oaktree Acquisition Corp. III Life Sciences (OACC) held an extraordinary general meeting on…
The massive redemption of ~81% of public shares present at the meeting severely depletes the trust account, leaving the SPARC with limited cash to pursue a business combination. The extension…
- BEARISH DEFA14AOct 16, 2026
Oaktree Acquisition Corp. III Life Sciences (OACC) postponed its extraordinary general meeting…
The postponement suggests management is struggling to gather enough votes for the extension. Monitor the outcome of the October 23 vote closely — failure to pass the extension would likely lead to…
- BEARISH 8-KOct 16, 2026
Oaktree Acquisition Corp. III Life Sciences postponed its extraordinary general meeting from…
Monitor the October 23 vote outcome closely — failure to extend the deadline would likely trigger liquidation and a return of trust proceeds to shareholders, while approval buys time for a deal…
- BEARISH DEFA14AOct 15, 2026
Oaktree Acquisition Corp. III Life Sciences filed a DEFA14A disclosing preliminary redemption…
The 13.3M share redemption (likely >50% of public float) signals severe lack of confidence in OAC's deal prospects. Monitor the October 16 vote outcome and any subsequent announcement of a target…
All OACC filing & press-release reports (6)
- 8-K reportOct 26, 2026
- DEFA14A reportOct 16, 2026
- 8-K reportOct 16, 2026
- DEFA14A reportOct 15, 2026
- 8-K reportOct 15, 2026
- DEF 14A reportOct 2, 2026